2-[3-(Aminomethyl)-3-bicyclo[4.1.0]heptanyl]acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[3-(Aminomethyl)-3-bicyclo[4.1.0]heptanyl]acetic acid
• 化学式: C₁₀H₁₇NO₂
• 分子量: 183.25
• InChiKey: IOYHERBFPMDMPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Method of treating cartilage damage
  申请人：——

  公开号：US20020072533A1

  公开（公告）日：2002-06-13

  The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  该发明涉及通过给予类似GABA的类似物，例如Formula1的化合物及其药学上可接受的盐，来预防或治疗软骨损伤的方法，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Method of treating tinnitus
  申请人：——

  公开号：US20030176504A1

  公开（公告）日：2003-09-18

  The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  这项发明涉及通过给予α2δ配体治疗耳鸣的方法，例如，给予一种符合化学式1的化合物及其药用盐，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS
  申请人：Dooley James David

  公开号：US20070213401A1

  公开（公告）日：2007-09-13

  The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  该发明涉及一种通过给予α2δ配体来治疗中枢神经系统疾病和其他疾病的方法，例如给予公式中的化合物或其药学上可接受的盐，其中R1为氢或直链或支链低碳基，n为4到6的整数。
• Combinations
  申请人：Field Mark John

  公开号：US20090036487A1

  公开（公告）日：2009-02-05

  The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred AChE inhibitors are donepezil (Aricept®), tacrine (Cognex®), rivastigmine (Exelon®), physostgmine (Synapton®), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil.

  本发明涉及一种α-2-δ配体和AChE抑制剂的组合物，用于治疗，尤其是神经病理性疼痛的治疗。特别优选的α-2-δ配体是加巴喷丁和普瑞巴林。特别优选的AChE抑制剂是多奈哌齐（阿力西普®），他克林（考宁思®），利伐司特（艾斯能®），毒扁豆碱（思纳普通®），加兰他敏（雷明®），甲磺酸甲氟磷酸（托品）, 新斯的明（普罗斯的明）和依可普齐。
• Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists
  申请人：Audoly Laurent Pascal

  公开号：US20090036495A1

  公开（公告）日：2009-02-05

  The instant invention relates to a combination of an EP4-receptor antagonist and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory, neuropathic, visceral and nociceptive pain.

  本发明涉及一种EP4受体拮抗剂和α-2-δ配体的组合物，及其药学上可接受的盐、制药组合物及其在治疗疼痛，特别是炎症性、神经病理性、内脏性和伤害性疼痛中的用途。